CSIMarket
 


Acasti Pharma Inc   (ACST)
Other Ticker:  
 
 

ACST's Operating Income Growth by Quarter and Year

Acasti Pharma Inc 's Operating Income results by quarter and year




ACST Operating Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter March - -38.07 -4.40 -2.30
III Quarter December - -4.25 -4.47 -1.96
II Quarter September -2.09 -5.11 -3.57 -8.03
I Quarter June -4.45 -4.73 -3.15 -4.12
FY   -6.54 -52.16 -15.59 -16.41



ACST Operating Income second quarter 2024 Y/Y Growth Comment
Acasti Pharma Inc in the second quarter 2024 recorded Operating Loss of $ -2.09 millions.

According to the results reported in the second quarter 2024, Acasti Pharma Inc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Acasti Pharma Inc ' s Operating Income no change of % ranks overall at the positon no. in the second quarter 2024.

Explain Operating Income growth


ACST Operating Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter March - - - -
III Quarter December - - - -
II Quarter September - - - -
I Quarter June - - - -
FY   - - - -

Financial Statements
Acasti Pharma Inc 's second quarter 2024 Operating Income $ -2.09 millions ACST's Income Statement
Acasti Pharma Inc 's second quarter 2023 Operating Income $ -5.11 millions Quarterly ACST's Income Statement
New: More ACST's historic Operating Income Growth >>


ACST Operating Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter March - - - -
III Quarter December - - - -
II Quarter September - - - -
I Quarter June - - - -
FY (Year on Year)   - - - -




Operating Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Acasti Pharma Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ACST's II. Quarter Q/Q Operating Income Comment
Even if Acasti Pharma Inc in the II. Quarter 2024 admitted Operating Loss of $ -2.09 millions, it should be said, that those numbers point to recovery compare to the -4.45 millions in the first quarter.

Within Major Pharmaceutical Preparations industry Acasti Pharma Inc achieved highest sequential Operating Income growth. While Acasti Pharma Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ACST's II. Quarter Q/Q Operating Income Comment
Even if Acasti Pharma Inc in the II. Quarter 2024 admitted Operating Loss of $ -2.09 millions, it should be said, that current results point to slight up side in contrast to the -4.45 millions in the first quarter.

Within Major Pharmaceutical Preparations industry Acasti Pharma Inc achieved highest sequential Operating Income growth. While Acasti Pharma Inc 's Operating Income growth quarter on quarter, overall rank is .


Acasti Pharma Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -48.86 $ -51.88 $ -52.16 $ -18.49 $ -18.72
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Acasti Pharma Inc ' has realized cumulative trailing twelve months Operating Loss of $ -49 millions in the Sep 30 2023 period.

Acasti Pharma Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Acasti Pharma Inc ' has realized cumulative trailing twelve months Operating Loss of $ -49 millions in the Sep 30 2023 period.

Acasti Pharma Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
ACST's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for ACST's Competitors
Operating Income Growth for Acasti Pharma Inc 's Suppliers
Operating Income Growth for ACST's Customers

You may also want to know
ACST's Annual Growth Rates ACST's Profitability Ratios ACST's Asset Turnover Ratio ACST's Dividend Growth
ACST's Roe ACST's Valuation Ratios ACST's Financial Strength Ratios ACST's Dividend Payout Ratio
ACST's Roa ACST's Inventory Turnover Ratio ACST's Growth Rates ACST's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Bio techne Corp-0.81%$ -0.808 millions
The Pennant Group Inc -1.16%$ -1.162 millions
Bio rad Laboratories Inc -1.99%$ -1.990 millions
Corcept Therapeutics Inc-2.37%$ -2.371 millions
Mettler toledo International Inc -3.07%$ -3.068 millions
Tenet Healthcare Corp-4.70%$ -4.698 millions
West Pharmaceutical Services Inc -4.78%$ -4.780 millions
Bruker Corporation-5.18%$ -5.179 millions
Henry Schein Inc-5.21%$ -5.213 millions
Hologic Inc-5.96%$ -5.962 millions
Sonida Senior Living Inc -6.27%$ -6.269 millions
Abbott Laboratories-6.95%$ -6.949 millions
Gilead Sciences Inc -7.54%$ -7.543 millions
Vertex Pharmaceuticals Inc-7.86%$ -7.864 millions
Bristol myers Squibb Company-9.18%$ -9.183 millions
Regeneron Pharmaceuticals Inc -9.21%$ -9.210 millions
National Research Corporation-10.39%$ -10.388 millions
Quest Diagnostics Inc-12.76%$ -12.755 millions
Bausch and Lomb Corp-13.04%$ -13.043 millions
Carlisle Companies Incorporated-13.87%$ -13.871 millions
Pediatrix Medical Group Inc -15.01%$ -15.015 millions
Community Health Systems Inc -15.20%$ -15.196 millions
Teva Pharmaceutical Industries Limited-15.27%$ -15.274 millions
Zynex inc -16.36%$ -16.362 millions
Entera Bio Ltd -16.72%$ -16.719 millions
Pacira Biosciences inc -16.76%$ -16.760 millions
Viatris Inc -19.35%$ -19.354 millions
Royalty Pharma Plc-21.21%$ -21.210 millions
Luna Innovations Inc-22.06%$ -22.057 millions
Avantor Inc -23.79%$ -23.785 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com